TOXICITY OF TWO CISPLATIN-BASED RADIOCHEMOTHERAPY REGIMENS FOR THE TREATMENT OF PATIENTS WITH STAGE III/IV HEAD AND NECK CANCER
|
|
- Benjamin Cobb
- 6 years ago
- Views:
Transcription
1 ORIGINAL ARTICLE TOXICITY OF TWO CISPLATIN-BASED RADIOCHEMOTHERAPY REGIMENS FOR THE TREATMENT OF PATIENTS WITH STAGE III/IV HEAD AND NECK CANCER Dirk Rades, MD, 1 Fabian Fehlauer, MD, 2 Mashid Sheikh-Sarraf, MD, 2 Nadja Kazic, MD, 3 Hiba Basic, MD, 3 Robert Poorter, MD, 4 Samer G. Hakim, MD, 5 Steven E. Schild, MD, 6 Juergen Dunst, MD 1 1 Department of Radiation Oncology, University Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany. Rades.Dirk@gmx.net 2 Department of Radiation Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany 3 Department of Radiation Oncology, University Hospital, Sarajevo, Bosnia-Herzegovina 4 Department of Radiation Oncology, Dr. Bernard Verbeeten Institute, Tilburg, The Netherlands 5 Department of Oral and Maxillofacial Surgery, University Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany 6 Department of Radiation Oncology, Mayo Clinic, Scottsdale, Arizona Accepted 2 April 2007 Published online 26 July 2007 in Wiley InterScience ( DOI: /hed Correspondence to: D. Rades VC 2007 Wiley Periodicals, Inc. Abstract: Background. This nonrandomized study compared 2 radiochemotherapy regimens for toxicity in 128 patients with stage III/IV head and neck cancer. Methods. Patients received conventionally fractionated radiotherapy. The total dose to primary tumor and involved lymph nodes did depend on preceding surgery. Patients received 66 to 70 Gy if surgery was not performed, 60 to 66 Gy after R0 resection, 66 Gy after R1 resection, and 70 to 72 Gy after R2 resection. Concurrent chemotherapy consisted of 3 courses cisplatin (100 mg/m 2 /d1,22,43) (group A, N ¼ 61) or 2 courses cisplatin (20 mg/m 2 /d1 5 þ 29 33)/5-fluorouracil (5-FU) (600 mg/m 2 /d1 5 þ 29 33) (group B, N ¼ 67). Results. Acute toxicity was more severe in group A, especially nausea/vomiting (p ¼.002), nephrotoxicity (p ¼.001), ototoxicity (p ¼.034), and hematotoxicity (p ¼.049). Forty-eight percent of group A and 10% of group B patients could not complete chemotherapy due to toxicity (p ¼.018). Late toxicity was similar (p ¼.99). Conclusion. Two courses of fractionated cisplatin (20 mg/ m 2 /d) and 5-FU were associated with significantly less acute toxicity than were 3 courses cisplatin (100 mg/m 2 /d). VC 2007 Wiley Periodicals, Inc. Head Neck 30: , 2008 Keywords: head and neck cancer; stage III/IV; radiochemotherapy; cisplatin; toxicity Locally advanced head and neck cancer carries a poor prognosis. Surgery followed by radiotherapy or radiochemotherapy is the treatment of choice. Several retrospective studies have suggested that postoperative radiotherapy improves locoregional control in patients with head and neck cancer when compared with surgery alone. 1 4 The potential benefit of postoperative radiochemotherapy when compared with postoperative radiotherapy alone is still controversial. The Intergroup study 0034 did not demonstrate a significant difference between radiotherapy plus 3 preceding courses of cisplatin/5-fluorouracil (5-FU) chemotherapy and radiotherapy alone with respect to locoregional Cisplatin-Based Radiochemotherapy Regimens HEAD & NECK DOI /hed February
2 control and overall survival. 5 In the study of the Radiation Therapy Oncology Group (RTOG), concurrent chemoradiotherapy with 3 courses of cisplatin was superior to radiotherapy alone for locoregional control, but not for overall survival. 6 The trial of the European Organization for Research and Treatment of Cancer (EORTC) suggested a benefit for chemoradiotherapy with 3 courses of cisplatin when compared with radiotherapy alone for both estimated 5-year locoregional control and survival. 7 However, the combined approach was associated with a substantial increase in acute toxicity. Definitive radiotherapy alone or definitive radiochemotherapy are both an option for patients with unresectable disease and serve as an alternative to surgery in appropriate cases. Radiotherapy alone, which had been the standard treatment for patients with unresectable tumors for many years, resulted in survival rates of less than 25% and 2- year locoregional control rates of less than 20% The treatment outcome may be improved by adding concurrent chemotherapy. 8,11 13 The majority of the available studies comparing radiochemotherapy versus radiotherapy alone for definitive head and neck cancer treatment suggested a survival benefit if concurrent chemotherapy was administered, 8,12 17 whereas a few studies did not demonstrate such a benefit. 18,19 The optimal radiochemotherapy regimen is a matter of debate, because most of the currently used regimens are associated with severe acute toxicity and even treatment-related deaths. Radiochemotherapy with 3 courses of 100 mg/m 2 cisplatin on days 1, 22, and 43 is the most frequently applied regimen, either as definitive or as adjuvant treatment. However, the acute toxicity of this program is considerable. Marcial et al 20 reported life-threatening renal damage in patients receiving definitive radiochemotherapy. Al-Sarraf et al 21 reported 20% severe toxicities and 12% life-threatening toxicities in patients receiving adjuvant radiochemotherapy with 60 Gy plus 3 courses of 100 mg/m 2 cisplatin. An alternative radiochemotherapy program associated with less acute toxicity appears desirable. The vast majority of head and neck cancer studies that included chemotherapy have compared radiotherapy alone versus radiochemotherapy but have not compared different radiochemotherapy schedules. Thus, studies comparing different radiochemotherapy schedules for head and neck cancer treatment are required to determine regimens that provide effective treatment with the least toxicity possible. The present study compares standard radiochemotherapy with 3 courses of 100 mg/m 2 cisplatin on days 1, 22, and 43 to another cisplatin-based chemotherapy regimen consisting of 2 courses of fractionated cisplatin (20 mg/m 2 /d on days 1 5 and 29 33) and 5-fluorouracil (600 mg/m 2 /d on days 1 5 and 29 33) with respect to toxicity in the treatment of locally advanced head and neck cancer. MATERIALS AND METHODS Patients. Between January 1998 and January 2006, 128 patients with stage III/IV carcinoma of the head and neck (17 nasopharynx, 48 oropharynx, 34 oral cavity, 16 hypopharynx, 13 larynx) received concurrent radiochemotherapy, either as definitive or as adjuvant treatment. Criteria for inclusion in this retrospective study were as follows: histologically proven carcinoma arising from the nasopharynx, the oropharynx, the oral cavity, the hypopharynx, or the larynx, and tumor stage III or IV according to the American Joint Committee of Cancer (AJCC) criteria based on CT and direct examination with endoscopy. According to the administered chemotherapy regimen, the patients were divided in 2 groups (see section Chemotherapy). The treatment regimen was mainly related to interdisciplinary (study) protocols being favored at the institutions at certain periods of time. These protocols varied due to the controversy in determining the best treatment for locally advanced head and neck cancer. Each series of patients from the contributing centers represents a series of patients treated with a specific regimen over a certain period of time. Group A consisted of 61 patients who came from Hamburg (N ¼ 27, and 2006), Sarajewo (N ¼ 24, ), Luebeck (N ¼ 6, ), and Tilburg (N ¼ 4, ); Group B consisted of 67 patients who came from Hamburg (N ¼ 67, and ). In addition to the investigators from the participating centers, the principal investigator reviewed the patient files in order to assure that there was no relevant variation of treatment factors, which might have introduced a selection bias. The patient characteristics related to the 2 treatment groups are listed in Table 1. These patients have not been reported elsewhere. Chemotherapy. Group A (n ¼ 61): The concurrent chemotherapy consisted of cisplatin, which was 236 Cisplatin-Based Radiochemotherapy Regimens HEAD & NECK DOI /hed February 2008
3 Table 1. Patient characteristics, related to treatment groups. No. of patients (%) Group A (n ¼ 61) Group B (n ¼ 67) p value Age, y (52) 30 (45).62 >55 29 (48) 37 (55) Sex Female 21 (34) 19 (28).76 Male 40 (66) 48 (72) Eastern Cooperative Oncology Group (ECOG) performance status (92) 53 (79) (8) 14 (21) Tumor site Nasopharynx 12 (20) 5 (8).58 Oropharynx 24 (39) 24 (36) Oral Cavity 12 (20) 22 (33) Hypopharynx 7 (11) 9 (13) Larynx 6 (10) 7 (10) Histology Squamous cell 55 (90) 62 (93).92 carcinoma Others 6 (10) 5 (7) Histologic grade G (63) 42 (68).84 G3 20 (37) 20 (32) T classification (31) 14 (21) (69) 53 (79) N classification 0-2b 26 (43) 27 (40).94 2c-3 35 (57) 40 (60) American Joint Committee on Cancer (AJCC) stage 3 15 (25) 11 (16) (75) 56 (84) Surgery Yes 32 (52) 35 (52).99 No 29 (48) 32 (48) Hemoglobin level pre-radiotherapy, g/dl <12 28 (46) 26 (39) (54) 41 (61) Note: Group A: radiotherapy plus 3 concurrent courses of cisplatin; Group B: radiotherapy plus 2 concurrent courses of cisplatin/5-fluororuracil. administered intravenously at a dose of 100 mg/ m 2 of body-surface area on days 1, 22, and 43 of the course of radiotherapy. The patients received 1500 ml of hydration given over 90 minutes before administration of cisplatin plus 20 to 40 mg of furosemide, and usually 4 to 8 mg of ondansetrone. Cisplatin was administered over 60 minutes, followed by another 1500 ml of hydration. The chemotherapy was administered by the radiation oncologists. The median cumulative cisplatin dose administered in group A patients was 300 mg/m 2 (range, mg/m 2 ) of body-surface area. Group B (n ¼ 67): The concurrent chemotherapy consisted of cisplatin administered intravenously at a dose of 20 mg/m 2 of body-surface area on days 1 to 5 and 29 to 33 of the course of radiotherapy, as well as of 5-fluorouracil (5-FU) administered intravenously as a continuous infusion for 120 hours at a daily dose of 600 mg/m 2 of body-surface area on days 1 to 5 and 29 to 33 of the course of radiotherapy. On each day of cisplatin administration, the patients received 1000 ml of hydration given over 60 minutes before administration of cisplatin plus 20 to 40 mg of furosemide, and mostly 4 to 8 mg of ondansetrone. Cisplatin was administered over 30 minutes, followed by another 1000 ml of hydration. Also in this group, the chemotherapy was administered by the radiation oncologists. The median cumulative cisplatin dose administered in group B patients was 200 mg/m 2 (range, mg/m 2 ) of body-surface area. Radiotherapy. All patients received conventionally fractionated radiotherapy (5 fractions per week) with doses per fraction of 2.0 Gy. Maximal and minimal target-volume doses and the maximal dose delivered to the spinal cord were recorded. Radiotherapy was performed with a linear accelerator and 4 to 6 megavoltage (MV) photons, as well as 10 to 12 MV electrons for parts of the posterior cervical lymph nodes, to limit the dose to the spinal cord to 45 Gy. The total dose delivered to the primary tumor and to the involved lymph nodes (according to CT) depended on preceding surgery. The total doses and the extent of resection related to the 2 treatment groups A and B are summarized in Table 2. The total dose to the other cervical and supraclavicular lymph nodes was 50 to 60 Gy. The total radiation doses also depended on interdisciplinary (study) protocols favored at the various treating institutions. Study Endpoints, Follow-Up, and Statistics. Both treatment groups were compared for acute and late toxicity. Acute toxicity was evaluated according to the Common Toxicity Criteria (CTC version 2.0), 22 and late toxicity according to the RTOG criteria. 23 Late toxicity was defined as toxicity occurring later than 90 days after radiochemotherapy was started. During radiotherapy the patients were prospectively and consistently followed for toxicity once a week, and after radiotherapy the patients were followed at regular intervals (usually every Cisplatin-Based Radiochemotherapy Regimens HEAD & NECK DOI /hed February
4 Table 2. Extent of resection and total radiation doses related to the treatment groups A and B. No. of patients (%) Total radiation dose Group A Group B R0 resection plus 60 Gy (N ¼ 24) R0 resection plus 64 Gy (N ¼ 13) 6 7 R0 resection plus 66 Gy (N ¼ 4) 2 2 R1 resection plus 66 Gy (N ¼ 15) 5 10 R2 resection plus 70 Gy (N ¼ 8) 3 5 R2 resection plus 72 Gy (N ¼ 3) Gy without surgery 2* 6 70 Gy without surgery 27** 26*** Note: R0, no residual tumor; R1, microscopically residual tumor; R2, macroscopically residual tumor. *One group A patient did not complete radiotherapy due to treatmentrelated death. **Two group A patients did not complete radiotherapy due to treatment-related death. ***One group B patient did not complete radiotherapy due to treatmentrelated death. 3 6 months) or until death. The median follow-up was 12 months (range, 0 66 months) in the entire cohort, 13 months (range, 0 66 months) in group A, and 11 months (range, 0 66 months) in group B. The relatively short follow-up is a reflection of early analysis rather than of low overall survival. Uncompleted chemotherapy was defined either as not all planned chemotherapy courses given or as a dose reduction of at least 25% during 1 or 2 courses. Patient characteristics and toxicity were compared with the chi-square test. RESULTS Significantly (p ¼.018) more group A patients (29/ 61, 48%) could not complete the chemotherapy due to acute toxicity than group B patients (7/67, 10%). In group A, 14 patients received only 1 course of chemotherapy (100 mg/m 2 of cisplatin; 33% of the prescribed cumulative dose), and another 14 patients received only 2 courses of cisplatin (200 m 2 of cisplatin; 67% of the prescribed cumulative dose). One patient received 1 complete course and 1 course with a 25% dose reduction (175 m 2 of cisplatin; 58% of the prescribed cumulative dose). In group B, 4 patients received only 1 course of chemotherapy (100 mg/m 2 of cisplatin; 50% of the prescribed cumulative dose), and 3 patients received 1 complete course of chemotherapy plus 1, 2, and 3 days of the second course, respectively (120, 140, and 160 mg/m 2 of cisplatin; 60%, 70%, and 80% of the prescribed cumulative dose). Of the 29 group A patients who did not complete the chemotherapy, 8 patients received only 60 Gy of irradiation (after R0 resection). In these 8 patients, only 2 courses of 100 mg/m 2 cisplatin were planned. However, the patients experienced serious acute toxicity after the first course (grade 3 4 hematotoxicity in 5 patients, grade 2 nephrotoxicity in 3 patients, grade 3 vomiting in 3 patients, grade 2 ototoxicity in 1 patient), and the second course cisplatin was either not administered or given with a dose reduction of at least 25%. Additionally, significantly more group A patients developed at least 1 grade 3 4 toxicity considered to be chemotherapy induced (59% vs 21%, p ¼.003), such as nephrotoxicity, ototoxicity, nausea/vomiting, hematotoxicity, and treatmentrelated death due to pneumonia or sepsis following neutropenia (Figure 1). Due to the fact that the antiemetic regimen may be considered less than the standard treatment in many other centers worldwide, the toxicity rates were recalculated without nausea/vomiting. Again, significantly more group A patients developed at least one grade 3 4 toxicity considered to be chemotherapy induced (48% vs 18%, p ¼.005). The acute toxicity most likely radiotherapy induced, such as mucositis, skin toxicity within the radiation fields, and xerostomia, was comparable in both treatment groups (Figure 1). Late toxicity such as late xerostomia, late skin toxicity, cervical fibrosis, and cervical lymph edema was similar in both groups (Figure 2). Seven percent of the group A patients and 10% of the group B patients developed grade 3 late xerostomia, and 7% (group A) and 13% (group B) developed cervical fibrosis. No grade 4 late toxicity was observed. According to the Kaplan Meier analyses 24 for the entire cohort, the 2-year rate of locoregional control was 70%, the 2-year rate of metastasisfree survival was 69%, and the 2-year rate of overall survival was 63%, respectively. The 2-year locoregional control rates were 72% for group A patients and 66% for group B patients (p ¼.32). The 2-year metastasis-free survival rates were 77% and 68%, respectively (p ¼.92), and the 2- year survival rates were 68% and 56%, respectively (p ¼.82). DISCUSSION Very few reports have compared various radiochemotherapy regimens for locally advanced head and neck cancer. The present study compared 2 different radiochemotherapy programs (group A: 3 courses of 100 mg cisplatin alone on days 1, 22, 238 Cisplatin-Based Radiochemotherapy Regimens HEAD & NECK DOI /hed February 2008
5 FIGURE 1. Acute toxicity: Comparison of the 2 treatment groups for acute toxicity in terms of Common Toxicity Criteria (CTC) grade 2 3 nephrotoxicity, grade 2 3 ototoxicity, grade 3 4 nausea/vomiting, grade 3 4 hematotoxicity, treatment-related deaths (pneumonia or sepsis following neutropenia) (top), and grade 3 4 toxicity related to radiotherapy (mucositis, skin toxicity, xerostomia) (bottom). 43 vs group B: 2 courses of 20 mg/m 2 cisplatin/ 600 mg/m 2 5-FU on days 1 5 and 29 33). However, one has to be aware of the limitations of the study presented here. The retrospective nature of the study and the heterogeneity of the patients should be taken into account when interpreting this analysis. The patient population included those treated with definitive chemoradiotherapy alone as well as postoperative patients with R0, R1, and R2 resections. Thus, a selection bias may have been introduced. The radiochemotherapy schedule administered in group A was associated with significantly more acute toxicity than the schedule administered in group B, especially in terms of nephrotoxicity, hematotoxicity, and nausea/vomiting. This may be explained by the fact that group A patients received more cisplatin than group B patients. Adding 5-FU was tolerated in group B patients, because they received less cisplatin and because cisplatin was fractionated. Fractionated administration of cisplatin (20 mg/m 2 /day for 5 days) may FIGURE 2. Late toxicity: Comparison of the 2 treatment groups for Radiation Therapy Oncology Group (RTOG) grade 2 3 toxicity (xerostomia, skin toxicity, cervical fibrosis, cervical lymph edema). Cisplatin-Based Radiochemotherapy Regimens HEAD & NECK DOI /hed February
6 be considered less toxic than a single dose of 100 mg/m 2 given in 1 day. Only 52% of the group A patients was able to receive the complete chemotherapy as initially planned, whereas the other 48% of the patients developed severe chemotherapy-related acute toxicity, which did not allow the administration of the complete chemotherapy. In the series of Forastiere et al, who treated patients with laryngeal cancer for organ preservation, the rate of high-grade toxic effects was greater with the chemotherapy-based regimens (81% with induction cisplatin/5-fu followed by radiotherapy and 82% with radiotherapy plus 3 courses of concurrent cisplatin) than with radiotherapy alone (66%). Seventy percent of the patients who received concurrent chemotherapy arms could receive all 3 courses of 100 mg/m 2 cisplatin. 19 This rate may be higher than in our series, because the authors did not consider patients who needed a reduction of the chemotherapy dose. In our study, both cessation of chemotherapy and dose reductions were considered as uncompleted chemotherapy. The randomized RTOG study compared 3 different radiochemotherapy regimens for toxicity and outcome in 241 patients with squamous cell carcinoma of the oral cavity, oropharynx, or hypopharynx. The patients received either 70 Gy givenin7weekswith10mg/m 2 cisplatin and 400 mg/m 2 of5-fudailyduringthelast10daysof radiotherapy (arm 1), 70 Gy in 13 weeks (given on alternating weeks) with daily hydroxyurea (1 g BID) and 800 mg/m 2 of 5-FU (arm 2), or 70 Gy in 7 weeks with weekly paclitaxel (30 mg/m 2 )and cisplatin (20 mg/m 2 )(arm3). 25 Ninety-two percent, 79%, and83% of patients on arms 1, 2, and 3,respectively,wereabletocompletetheirradiation as planned or with an acceptable variation. Fewer than 10% of patients had unacceptable deviations or incomplete chemotherapy in the 3 arms. Estimated 2-year disease-free and overall survival rates were 38.2% and 57.4% for arm 1, 48.6% and 69.4% for arm 2, and 51.3% and 66.6% for arm 3. The grade 4 toxicity rates were similar in the 3 groups, being 18%, 29%, and 23%, respectively. There were 3 deaths (4%) attributed to treatment toxicity in arm 1. All 3 deaths occurred subsequent to the chemotherapy delivery. Four and 5 patients died during or within 30 days of completion of their therapy on arms 2 and 3, respectively. The rates of treatment-related deaths are comparable to the 4% of our group A patients, but higher than the 1% of our group B patients. The acute toxicity that was likely related to radiotherapy, such as mucositis, skin toxicity, and xerostomia, did not significantly differ between the 2 groups. The late toxicity such as late xerostomia, late skin toxicity, cervical fibrosis, and cervical lymph edema was similar in both groups. Xerostomia and cervical fibrosis rates in our series (7% to 10% and 7% to 13%, respectively) were comparable to those of other schedules as reported by Calais et al, 13 who treated patients with advancedstage oropharynx carcinoma with definitive concurrent radiochemotherapy including 3 courses of a 4-day regimen of 70 mg/m 2 carboplatin and 600 mg/m 2 5-FU. They reported 9% grade 3 4 xerostomia and 11% grade 3 4 cervical fibrosis. In conclusion, for radiochemotherapy of stage III/IV head and neck cancer, the regimen including 2 courses of fractionated cisplatin (20 mg/m 2 /d on radiotherapy days 1 5 and 29 33) and 5-FU (600 mg/m 2 /d on radiotherapy days 1 5 and 29 33) was associated with significantly less acute toxicity than 3 courses of cisplatin (100 mg/m 2 on radiotherapy days 1, 22, and 43). Adding 5-FU was tolerated by group B patients, because these patients received less cisplatin and because cisplatin was fractionated. The results of this retrospective study need to be confirmed in a randomized trial. REFERENCES 1. Arriagada R, Eschwege F, Cachin Y, Richard JM. The value of combining radiotherapy with surgery in the treatment of hypopharyngeal and laryngeal cancers. Cancer 1983;51: Bartelink H, Breur K, Hart G, Annyas B, van Slooten E, Snow G. The value of postoperative radiotherapy as an adjuvant to radical neck dissection. Cancer 1983;52: Nisi KW, Foote RL, Bonner JA, McCaffrey TV. Adjuvant radiotherapy for squamous cell carcinoma of the tongue base: improved locoregional disease control compared with surgery alone. Int J Radiat Oncol Biol Phys 1998; 41: Regine WF, Valentino J, Sloan DA, et al. Postoperative radiation therapy for primary vs. recurrent squamous cell carcinoma of the head and neck: results of a comparative analysis. Head Neck 1999;21: Laramore GE, Scott CG, Al-Sarraf M, et al. Adjuvant chemotherapy for resectable squamous cell carcinoma of the head and neck: report on Intergroup Study Int J Radiat Oncol Biol Phys 1992;23: Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350: Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350: Cisplatin-Based Radiochemotherapy Regimens HEAD & NECK DOI /hed February 2008
7 8. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21: Vokes EE, Weichselbaum RR, Lipman SM, Hong WK. Head and neck cancer. N Engl J Med 1993;328: McKenna WG, Emami B. Recursive partitioning analysis of 2105 patients treated in Radiation Therapy Oncology Group studies of head and neck cancer. Cancer 1996; 77: Al-Sarraf M. Treatment of locally advanced head and neck cancer: historical and critical review. Cancer Control 2002;9: Denis F, Garaud P, Bardet E, et al. Final results of the French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004;22: Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1998;91: Wendt TG, Grabenbauer GG, Roedel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998;16: Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338: Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated radiation therapy with or without concurrent lowdose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 2000;18: Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;50: Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 2000;355: Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;348: Marcial VA, Pajak TF, Mohiuddin M, et al. Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Long-term results of the Radiation Therapy Oncology Group study Cancer 1990;66: Al-Sarraf M, Pajak TF, Byhardt RW, Beitler JJ, Salter MM, Cooper JS. Postoperative radiotherapy with concurrent cisplatin appears to improve locoregional control of advanced, resectable head and neck cancers: RTOG Int J Radiat Oncol Biol Phys 1997;37: Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000;47: Bruner DW, Wasserman T. The impact on quality of life by radiation late effects. Int J Radiat Oncol Biol Phys 1995;31: Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53: Garden AS, Harris J, Vokes EE, et al. Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol 2004;22: Cisplatin-Based Radiochemotherapy Regimens HEAD & NECK DOI /hed February
Accepted 28 April 2005 Published online 13 September 2005 in Wiley InterScience ( DOI: /hed.
DEFINING RISK LEVELS IN LOCALLY ADVANCED HEAD AND NECK CANCERS: A COMPARATIVE ANALYSIS OF CONCURRENT POSTOPERATIVE RADIATION PLUS CHEMOTHERAPY TRIALS OF THE EORTC (#22931) AND RTOG (#9501) Jacques Bernier,
More informationAccepted 20 April 2009 Published online 25 June 2009 in Wiley InterScience (www.interscience.wiley.com). DOI: /hed.21179
ORIGINAL ARTICLE DOCETAXEL, CISPLATIN, AND FLUOROURACIL INDUCTION CHEMOTHERAPY FOLLOWED BY ACCELERATED FRACTIONATION/CONCOMITANT BOOST RADIATION AND CONCURRENT CISPLATIN IN PATIENTS WITH ADVANCED SQUAMOUS
More informationThe Role of Concurrent Chemo-radiotherapy in Patients with Head and Neck Cancers: A Review
The Role of Concurrent Chemo-radiotherapy in Patients with Head and Neck Cancers: A Review M.D. Al-Sarraf 1 1 Williams Beaumont Hospital, Royal Oak, Michigan, USA Introduction In the past, radiotherapy
More informationJMSCR Vol 07 Issue 01 Page January 2019
www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v7i1.58 Pure Accelerated Radiotherapy
More informationNeoplasie del laringe Diagnosi e trattamento
Neoplasie del laringe Diagnosi e trattamento Venerdì 22 maggio 2015 Alessandria Trattamenti non chirurgici: Preservazione d organo, malattia localmente avanzata Marco C Merlano A.O. S.Croce e Carle, Ospedale
More informationSelf-Assessment Module 2016 Annual Refresher Course
LS16031305 The Management of s With r. Lin Learning Objectives: 1. To understand the changing demographics of oropharynx cancer, and the impact of human papillomavirus on overall survival and the patterns
More informationTitle. CitationInternational Journal of Clinical Oncology, 20(6): 1. Issue Date Doc URL. Rights. Type. File Information
Title Clinical outcomes of weekly cisplatin chemoradiother Sakashita, Tomohiro; Homma, Akihiro; Hatakeyama, Hir Author(s) Takatsugu; Iizuka, Satoshi; Onimaru, Rikiya; Tsuchiy CitationInternational Journal
More informationChemoradiation after Surgery for High-Risk Head and Neck Cancer Patients: How Strong Is the Evidence? Jacques Bernier and Jay S.
Chemoradiation after Surgery for High-Risk Head and Neck Cancer Patients: How Strong Is the Evidence? Jacques Bernier and Jay S. Cooper The Oncologist 2005, 10:215-224. doi: 10.1634/theoncologist.10-3-215
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
Douglas et al. BMC Cancer 2012, 12:425 RESEARCH ARTICLE Open Access A new score predicting the survival of patients with spinal cord compression from myeloma Sarah Douglas 1, Steven E Schild 2 and Dirk
More informationComparative study of Gemcitabine versus Cisplatin concurrent with radiotherapy for locally advanced head and neck cancer
Journal of Cancer Treatment and Research 2014; 2(4): 37-44 Published online August 30, 2014 (http://www.sciencepublishinggroup.com/j/jctr) doi: 10.11648/j.jctr.20140204.12 Comparative study of Gemcitabine
More informationThe management of advanced supraglottic and
ORIGINAL ARTICLE ORGAN PRESERVATION FOR ADVANCED LARYNGEAL CARCINOMA Robert L. Foote, MD, 1 R. Tyler Foote, 1 Paul D. Brown, MD, 1 Yolanda I. Garces, MD, 1 Scott H. Okuno, MD, 2 Scott E. Strome, MD 3 1
More informationORIGINAL ARTICLE. Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck for Organ Preservation and Palliation
ORIGINAL ARTICLE Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck for Organ Preservation and Palliation Michael E. Poole, PA-C, MPH; Scott L. Sailer, MD; Julian G. Rosenman,
More informationProtocol of Radiotherapy for Head and Neck Cancer
106 年 12 月修訂 Protocol of Radiotherapy for Head and Neck Cancer Indication of radiotherapy Indication of definitive radiotherapy with or without chemotherapy (1) Resectable, but medically unfit, or high
More informationKey words: Head-and-neck cancer, Chemoradiation, Concomitant Boost Radiation, Docetaxel. Materials and Methods
Weekly Cisplatin and Docetaxel plus Concomitant Boost Concurrently with Radiation Therapy in the Treatment of Locally Advanced Head And Neck Cancer: Phase II Trial Abd El Halim Abu-Hamar, MD 1, Naser Abd
More informationConcurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary
Original article Annals of Oncology 14: 1306 1311, 2003 DOI: 10.1093/annonc/mdg330 Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary A. Argiris
More informationORIGINAL ARTICLE. David E. Schuller, MD; Enver Ozer, MD; Amit Agrawal, MD; John C. Grecula, MD; Chris A. Rhoades, MD; Donn C.
ORIGINAL ARTICLE Multimodal Intensification Regimens for Advanced, Resectable, Previously Untreated Squamous Cell Cancer of the Oral Cavity, Oropharynx, or Hypopharynx A 12-Year Experience David E. Schuller,
More informationLocally advanced head and neck cancer
Locally advanced head and neck cancer Radiation Oncology Perspective Petek Erpolat, MD Gazi University, Turkey Definition and Management of LAHNC Stage III or IV cancers generally include larger primary
More informationCetuximab/cisplatin and radiotherapy in HNSCC: is there a favorite choice?
Cent. Eur. J. Med. 9(2) 2014 279-284 DOI: 10.2478/s11536-013-0154-9 Central European Journal of Medicine Cetuximab/cisplatin and radiotherapy in HNSCC: is there a favorite choice? Jacopo Giuliani* 1, Marina
More informationHEAD AND NECK CANCER TREATMENT REGIMENS (Part 1 of 5)
HEAD AND NECK CANCER TREATMENT S (Part 1 of 5) Clinical Trials: The National Comprehensive Cancer Network (NCCN) recommends cancer patient participation in clinical trials as the gold standard for treatment.
More informationIntroduction. Jong Hoon Lee, MD 1. Sang Nam Lee, MD 2 Jin Hyoung Kang, MD 3 Min Sik Kim, MD 4 Dong Il Sun, MD 2 Yeon-Sil Kim, MD 2
pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2013;45(1):31-39 Original Article http://dx.doi.org/10.4143/crt.2013.45.1.31 Open Access Adjuvant Postoperative Radiotherapy with or without Chemotherapy
More informationThe PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer
The PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer Robert I. Haddad, Guilherme Rabinowits, Roy B. Tishler,
More informationACR Appropriateness Criteria Adjuvant Therapy for Resected Squamous Cell Carcinoma of the Head and Neck EVIDENCE TABLE
1. Johnson JT, Barnes EL, Myers EN, Schramm VL, Jr., Borochovitz D, Sigler BA. The extracapsular spread of tumors in cervical node metastasis. Arch Otolaryngol 1981; 107(1):75-79.. Snow GB, Annyas AA,
More informationComparison of acute toxicities and response of standard chemo radiation versus hyper fractionated radiotherapy in head and neck cancers
Original Research Article Comparison of acute toxicities and response of standard chemo radiation versus hyper fractionated radiotherapy in head and neck cancers Kuppa Prakash 1*, A. Ravi Chandran 2, M.
More informationTRANSPARENCY COMMITTEE OPINION. 18 October 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 October 2006 ERBITUX 2 mg/ml, Solution for infusion 1 bottle of 50 ml (CIP: 565 806 9) Applicant : MERCK LIPHA
More informationComparison of acute toxicities of two chemotherapy schedules for head and neck cancers
Original Article Free full text available from www.cancerjournal.net Comparison of acute toxicities of two chemotherapy schedules for head and neck cancers Geeta SN, TK Padmanabhan, J Samuel, K Pavithran*,
More informationHEAD AND NECK CANCER TREATMENT REGIMENS (Part 1 of 5)
HEAD AND NECK CANCER TREATMENT S (Part 1 of 5) Clinical Trials: The National Comprehensive Cancer Network (NCCN) recommends cancer patient participation in clinical trials as the gold standard for treatment.
More informationAccepted 12 August 2010 Published online 15 December 2010 in Wiley Online Library (wileyonlinelibrary.com). DOI: /hed.21624
ORIGINAL ARTICLE IMPACT OF EARLY PERCUTANEOUS ENDOSCOPIC GASTROSTOMY TUBE PLACEMENT ON NUTRITIONAL STATUS AND HOSPITALIZATION IN PATIENTS WITH HEAD AND NECK CANCER RECEIVING DEFINITIVE CHEMORADIATION THERAPY
More informationRADIO- AND RADIOCHEMOTHERAPY OF HEAD AND NECK TUMORS. Zoltán Takácsi-Nagy PhD Department of Radiotherapy National Institute of Oncology, Budapest 1.
RADIO- AND RADIOCHEMOTHERAPY OF HEAD AND NECK TUMORS Zoltán Takácsi-Nagy PhD Department of Radiotherapy National Institute of Oncology, Budapest 1. 550 000 NEW PATIENTS/YEAR WITH HEAD AND NECK CANCER ALL
More informationNon-surgical treatment for locally advanced head and neck squamous cell carcinoma: beyond the upper limit
Editorial Non-surgical treatment for locally advanced head and neck squamous cell carcinoma: beyond the upper limit Hiroto Ishiki, Satoru Iwase Department of Palliative Medicine, The Institute of Medical
More informationMANAGEMENT OF CA HYPOPHARYNX
MANAGEMENT OF CA HYPOPHARYNX GENERAL TREATMENT RECOMMENDATIONS BASED ON HYPOPHARYNX TUMOR STAGE For patients presenting with early-stage definitive radiotherapy alone or voice-preserving surgery are viable
More informationConcurrent Chemoradiotherapy with Cisplatin and Docetaxel for Advanced Head and Neck Cancer. A Phase I Study
Concurrent Chemoradiotherapy with Cisplatin and Docetaxel for Advanced Head and Neck Cancer. A Phase I Study HIDENORI INOHARA 1, TAKEHIRO INOUE 2, SHIRO AKAHANI 1, YOSHIFUMI YAMAMOTO 1, YUKINORI TAKENAKA
More informationSaptarshi Ghosh*, Pamidimukkala Brahmananda Rao, P Ravindra Kumar, Surendra Manam
RESEARCH ARTICLE Concurrent Chemoradiation with Weekly Cisplatin for the Treatment of Head and Neck Cancers: an Institutional Study on Acute Toxicity and Response to Treatment Saptarshi Ghosh*, Pamidimukkala
More informationGuillaume Janoray, Yoann Pointreau, Pascal Garaud, Sophie Chapet, Marc Alfonsi, Christian Sire, Eric Jadaud, Gilles Calais
JNCI J Natl Cancer Inst (016) 108(4): djv368 doi:10.1093/jnci/djv368 First published online December 16, 015 Article Long-Term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy
More informationPostoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer
The new england journal of medicine original article Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer Jacques Bernier, M.D., Ph.D., Christian
More informationORIGINAL ARTICLE CHEMOTHERAPY ALONE FOR ORGAN PRESERVATION IN ADVANCED LARYNGEAL CANCER
ORIGINAL ARTICLE CHEMOTHERAPY ALONE FOR ORGAN PRESERVATION IN ADVANCED LARYNGEAL CANCER Vasu Divi, MD, 1 * Francis P. Worden, MD, 1,2 * Mark E. Prince, MD, 1 Avraham Eisbruch, MD, 3 Julia S. Lee, MD, 4
More informationORIGINAL ARTICLE. Examining the Need for Neck Dissection in the Era of Chemoradiation Therapy for Advanced Head and Neck Cancer
ORIGINAL ARTICLE Examining the Need for Neck Dissection in the Era of Chemoradiation Therapy for Advanced Head and Neck Cancer Laura A. Goguen, MD; Marshall R. Posner, MD; Roy B. Tishler, MD, PhD; Lori
More informationLaryngeal Preservation Using Radiation Therapy. Chemotherapy and Organ Preservation
1 Laryngeal Preservation Using Radiation Therapy 1903: Schepegrell was the first to perform radiation therapy for the treatment of laryngeal cancer Conventional external beam radiation produced disappointing
More informationOrgan-Preservation Strategies in head and neck cancer. Teresa Bonfill Abella Oncologia Mèdica Parc Taulí Sabadell. Hospital Universitari
Organ-Preservation Strategies in head and neck cancer Teresa Bonfill Abella Oncologia Mèdica Parc Taulí Sabadell. Hospital Universitari Larynx Hypopharynx The goal of treatment is to achieve larynx preservation
More informationOutcomes for patients with head and neck squamous cell carcinoma presenting with N3 nodal disease
Witek et al. Cancers of the Head & Neck (2017) 2:8 DOI 10.1186/s41199-017-0027-z Cancers of the Head & Neck RESEARCH Open Access Outcomes for patients with head and neck squamous cell carcinoma presenting
More informationTreatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy
Korean J Hepatobiliary Pancreat Surg 2011;15:152-156 Original Article Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Suzy Kim 1,#, Kyubo
More informationHead and Neck Reirradiation: Perils and Practice
Head and Neck Reirradiation: Perils and Practice David J. Sher, MD, MPH Department of Radiation Oncology Dana-Farber Cancer Institute/ Brigham and Women s Hospital Conflicts of Interest No conflicts of
More information5/20/ ) Haffty GB: Concurrent chemoradiation in the treatment of head and neck cancer. Hematol. Oncol. Clin: North Am.
Prague, 24-25 25 April 29 ALTERNATING CHEMORADIATION: FOR WHOM? M. Merlano MD Holy Cross Gen. Hospital Cuneo - Italy ALTERNATING CHEMORADIATION: FOR WHOM? Definition of alternating chemoradiation Targets
More informationDe-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist
De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to
More informationA phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas
Radiotherapy and Oncology 79 (2006) 34 38 www.thegreenjournal.com Phase II trial A phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head
More informationConcomitant Chemoradiotherapy with Altered Cisplatin Regimen in Management of Locally Advanced Head and Neck Cancers
Research Article imedpub Journals www.imedpub.com DOI: http://www.imedpub.com/brain-behaviour-and-cognitive-sciences/ Concomitant Chemoradiotherapy with Altered Cisplatin Regimen in Management of Locally
More informationAdjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support
Adjuvant Therapy in Locally Advanced Head and Neck Cancer Ezra EW Cohen University of Chicago Financial Support This program is made possible by an educational grant from Eli Lilly Oncology, who had no
More informationNasopharyngeal Cancer:Role of Chemotherapy
Nasopharyngeal Cancer:Role of Chemotherapy PANAGIOTIS KATSAOUNIS Medical Oncologist IASO GENERAL HOSPITAL Athens, 16/9/2017 2 nd Hellenic Multidisciplinary Conference on Head and Neck Cancer INTRODUCTION
More informationORIGINAL ARTICLE. Harold Lau, MD; Tien Phan, MD; Jack MacKinnon, MD; T. Wayne Matthews, MD
ORIGINAL ARTICLE Absence of Planned Neck Dissection for the N2-N3 Neck After Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck Harold Lau, MD; Tien Phan, MD; Jack MacKinnon,
More informationWeekly versus every-three-weeks platinumbased chemoradiation regimens for head and neck cancer
Melotek et al. Journal of Otolaryngology - Head and Neck Surgery (2016) 45:62 DOI 10.1186/s40463-016-0175-x ORIGINAL RESEARCH ARTICLE Weekly versus every-three-weeks platinumbased chemoradiation regimens
More informationNeoadjuvant Chemotherapy in Locally Advanced Squamous Cell Cancer of Head and Neck. Mei Tang, MD
Neoadjuvant Chemotherapy in Locally Advanced Squamous Cell Cancer of Head and Neck Mei Tang, MD Head and Neck Cancer Worldwide New cases : 644,000 Cancer deaths: 350,000 About 5% of all cancers Local Recurrence:
More informationCisplatin100 plus Radiotherapy for locally Advanced Squamous Cell Carcinoma Head and Neck
Cisplatin100 plus Radiotherapy for locally Advanced Squamous Cell Carcinoma Head and Neck Indication: 1) Concomitant chemo-radiotherapy for locally advanced squamous cell carcinoma head and neck 2) Post-operative
More informationComparison of Futility Monitoring Methods Using RTOG Clinical Trials. Q. Ed Zhang, PhD
Comparison of Futility Monitoring Methods Using RTOG Clinical Trials Q. Ed Zhang, PhD 1 Futility Monitoring Definition: Monitoring for early determination that trial results will not be in favor of H 1
More informationHPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view. Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium
HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium DISCLOSURE OF INTEREST Nothing to declare HEAD AND NECK CANCER -HPV
More informationRAMY R. GHALI, M.D.*; EMAN EL-SHARAWY, M.D.*; AZZA M. ADEL, M.D.* and SAMER A. IBRAHIM, M.D.**
Med. J. Cairo Univ., Vol. 79, No. 2, June: 13-18, 2011 www.medicaljournalofcairouniversity.com Induction Docetaxel, Cisplatin and 5 Fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy Versus Concomitant
More informationOncologist. The. Outcomes Research. Changes in Survival in Head and Neck Cancers in the Late 20th and Early 21st Century: A Period Analysis
The Oncologist Outcomes Research Changes in Survival in Head and Neck Cancers in the Late 20th and Early 21st Century: A Period Analysis DIANNE PULTE, a,b HERMANN BRENNER a a Division of Clinical Epidemiology
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More information[ ] (2010) Clinical Guideline
98 2010 3 8 2 China Journal of Oral and Maxillofacial Surgery Vol.8 No.2 March2010 [ ]1672-3244(2010)02-0098-09 Clinical Guideline [ ] 3%~5% 90% 3 5 65% 5 30% 2009 NCCN [ ] ; ; [ ] R739.8 [ ] A The protocol
More informationUpdate on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer
Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy NACT in Cervical Cancer NACT Stage -IB2 -IIA>4cm
More informationEmerging Role of Immunotherapy in Head and Neck Cancer
Emerging Role of Immunotherapy in Head and Neck Cancer Jared Weiss, MD Associate Professor of Medicine and Section Chief of Thoracic and Head/Neck Oncology UNC Lineberger Comprehensive Cancer Center Copyright
More informationHypofractionated palliative radiotherapy for advanced head and neck cancer: The IHF2SQ regimen
ORIGINAL ARTICLE Hypofractionated palliative radiotherapy for advanced head and neck cancer: The IHF2SQ regimen Laurie Monnier, MD, 1 * Emmanuel Touboul, MD, PhD, 1 Catherine Durdux, MD, 2 Philippe Lang,
More informationCombined Modality Treatment of Anal Carcinoma
Combined Modality Treatment of Anal Carcinoma F. ROELOFSEN, a H. BARTELINK b a Bethesda Krankenhaus, Essen, Germany; b The Netherlands Cancer Institute/Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, The
More informationParadigm Shift in the Treatment of Head and Neck Cancer: The Role of Neoadjuvant Chemotherapy
This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Paradigm Shift in the Treatment of Head and Neck Cancer: The
More informationThe New England Journal of Medicine HYPERFRACTIONATED IRRADIATION WITH OR WITHOUT CONCURRENT CHEMOTHERAPY FOR LOCALLY ADVANCED HEAD AND NECK CANCER
HYPERFRACTIONATED IRRADIATION WITH OR WITHOUT CONCURRENT CHEMOTHERAPY FOR LOCALLY ADVANCED HEAD AND NECK CANCER DAVID M. BRIZEL, M.D., MARY E. ALBERS, M.D., SAMUEL R. FISHER, M.D., RICHARD L. SCHER, M.D.,
More informationDegree of nephrotoxicity after intermediate- or high-dose cisplatin-based chemoradiotherapy in patients with locally advanced head and neck cancer
ORIGINAL ARTICLE Degree of nephrotoxicity after intermediate- or high-dose cisplatin-based chemoradiotherapy in patients with locally advanced head and neck cancer Chantal M. L. Driessen, MD, 1 Maike J.
More informationPractice teaching course on head and neck cancer management
28-29 October 2016 - Saint-Priest en Jarez, France Practice teaching course on head and neck cancer management IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org Nicolas Magné France
More informationChapter 5 Stage III and IVa disease
Page 55 Chapter 5 Stage III and IVa disease Overview Concurrent chemoradiotherapy (CCRT) is recommended for stage III and IVa disease. Recommended regimen for the chemotherapy portion generally include
More informationAccepted 12 April 2006 Published online 13 November 2006 in Wiley InterScience ( DOI: /hed.
ORIGINAL ARTICLE PHASE II ANALYSIS OF PACLITAXEL AND CAPECITABINE IN THE TREATMENT OF RECURRENT OR DISSEMINATED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK REGION Jens D Bentzen, MD, 1 Hanne Sand Hansen,
More informationLaryngeal Conservation
Laryngeal Conservation Sarah Rodriguez, MD Faculty Advisor: Shawn Newlands, MD, PhD The University of Texas Medical Branch Department of Otolaryngolgy Grand Rounds Presentation February 2005 Introduction
More informationTHE IMPACT OF THE TIME FACTOR ON THE OUTCOME OF A COMBINED TREATMENT OF PATIENTS WITH LARYN- GEAL CANCER
THE IMPACT OF THE TIME FACTOR ON THE OUTCOME OF A COMBINED TREATMENT OF PATIENTS WITH LARYN- GEAL CANCER Piotr Milecki 1, Grażyna Stryczyńska 1, Aleksandra Kruk-Zagajewska 2 Department of Radiotherapy,
More informationSTUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER
Contact: Anne Bancillon + 33 (0)6 70 93 75 28 STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Key results of 42 nd annual meeting of the American Society of Clinical
More informationAccepted 27 August 2009 Published online 2 November 2009 in Wiley InterScience ( DOI: /hed.
ORIGINAL ARTICLE ACCELERATED FRACTIONATION RADIOTHERAPY AND LATE INTENSIFICATION WITH 2 INTRA-ARTERIAL CISPLATIN INFUSIONS FOR LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA Kwok Hung Yu, FRCR,
More informationJ Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 34 DECEMBER 1 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Phase III Study Comparing Cisplatin Plus Fluorouracil to Paclitaxel, Cisplatin, and Fluorouracil Induction Chemotherapy
More informationMichael Schlumpf 1,2, Claude Fischer 1,3, Diana Naehrig 1,4, Christoph Rochlitz 1 and Martin Buess 1,2*
Schlumpf et al. BMC Cancer 2013, 13:610 RESEARCH ARTICLE Open Access Results of concurrent radio-chemotherapy for the treatment of head and neck squamous cell carcinoma in everyday clinical practice with
More informationAcute and late adverse effects of breast cancer radiation: Two hypo-fractionation protocols
ORIGINAL ARTICLES Acute and late adverse effects of breast cancer radiation: Two hypo-fractionation protocols Mohamed Abdelhamed Aboziada 1, Samir Shehata 2 1 Department of Radiation Oncology, South Egypt
More informationLymph node ratio as a prognostic factor in head and neck cancer patients
Chen et al. Radiation Oncology (2015) 10:181 DOI 10.1186/s13014-015-0490-9 RESEARCH Open Access Lymph node ratio as a prognostic factor in head and neck cancer patients Chien-Chih Chen 1*, Jin-Ching Lin
More informationLaryngeal and hypopharyngeal cancers
Laryngeal and hypopharyngeal cancers Induction Chemotherapy in combined modality approaches Atenas 16.09.2017 Ana Ferreira Castro, MD Medical Oncology Centro Hospitalar do Porto Instituto de Ciências Biomédicas
More informationRadiotherapy related skin toxicity (RAREST-01): Mepitel film versus standard care in patients with locally advanced head-and-neck cancer
Narvaez et al. BMC Cancer (2018) 18:197 https://doi.org/10.1186/s12885-018-4119-x STUDY PROTOCOL Radiotherapy related skin toxicity (RAREST-01): Mepitel film versus standard care in patients with locally
More informationAdjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009
HIGHLIGHT ARTICLE - Slide Show Adjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009 Muhammad Wasif Saif
More informationGastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D.
Gastroesophageal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. Haddock M.D. Mayo Clinic Rochester, MN Locally Advanced GE Junction ACA CT S CT or CT S CT/RT Proposition Chemoradiation
More informationRole of Concomitant Chemoradiation in Locally Advanced Head and Neck Cancers
DOI:http://dx.doi.org/10.7314/APJCP.2014.15.10.4147 Role of Concomitant Chemoradiation in Locally Advanced Head and Neck Cancers RESEARCH ARTICLE Role of Concomitant Chemoradiation in Locally Advanced
More informationNasopharyngeal Cancer/Multimodality Treatment
Nasopharyngeal Cancer/Multimodality Treatment PANAGIOTIS KATSAOUNIS Medical Oncologist IASO GENERAL HOSPITAL Athens, 22/10/2016 1 st Hellenic Multidisciplinary Conference on Head and Neck Cancer INTRODUCTION
More informationSimultaneous Integrated Boost or Sequential Boost in the Setting of Standard Dose or Dose De-escalation for HPV- Associated Oropharyngeal Cancer
Simultaneous Integrated Boost or Sequential Boost in the Setting of Standard Dose or Dose De-escalation for HPV- Associated Oropharyngeal Cancer Dawn Gintz, CMD, RTT Dosimetry Coordinator of Research and
More informationTREATMENT TIME & TOBACCO: TWIN TERRORS Of H&N Therapy
TREATMENT TIME & TOBACCO: TWIN TERRORS Of H&N Therapy Anurag K. Singh, MD Professor of Medicine University at Buffalo School of Medicine Professor of Oncology Director of Radiation Research Roswell Park
More informationjournal of medicine The new england Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer abstract
The new england journal of medicine established in 1812 november 27, 2003 vol. 349 no. 22 Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer Arlene A. Forastiere,
More informationJOURNAL SCAN FOR IJHNS
JOURNAL SCAN FOR IJHNS IJHNS Journal Scan for IJHNS Meta-analysis of Chemotherapy in Head and Neck Cancer (MACH-NC): An Update on 93 Randomized Trials and 17,346 Patients Jean-Pierre Pignon A, Aurélie
More informationChemo-reirradiation in Persistent/Recurrent Head and Neck Cancers
Jpn J Clin Oncol 2004;34(2)61 68 Original Articles Chemo-reirradiation in Persistent/Recurrent Head and Neck Cancers Yoodhvir Singh Nagar, Shalini Singh and Niloy Ranjan Datta Department of Radiotherapy,
More informationPre- Versus Post-operative Radiotherapy
Postoperative Radiation and Chemoradiation: Indications and Optimization of Practice Dislosures Clinical trial support from Genentech Inc. Sue S. Yom, MD, PhD Associate Professor UCSF Radiation Oncology
More informationPost-Operative Concurrent Chemoradiation with Mitomycin-C for Advanced Head and Neck Cancer
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 2006 Post-Operative Concurrent Chemoradiation with Mitomycin-C for
More informationResponse Evaluation Of Accelerated Fractionation With Concomitant Boost Chemoradiation In Locally Advanced Squamous Cell Head And Neck Cancer
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 15, Issue 2 Ver. IV (Feb. 2016), PP 27-32 www.iosrjournals.org Response Evaluation Of Accelerated Fractionation
More informationSeptember 10, Dear Dr. Clark,
September 10, 2015 Peter E. Clark, MD Chair, NCCN Bladder Cancer Guidelines (Version 2.2015) Associate Professor of Urologic Surgery Vanderbilt Ingram Cancer Center Nashville, TN 37232 Dear Dr. Clark,
More informationDiagnosis and what happens after referral
Diagnosis and what happens after referral Dr Kate Newbold Consultant in Clinical Oncology The Royal Marsden Women's cancers Breast cancer introduction 1 Treatment Modalities Early stage disease -larynx
More informationRadio(chemo)therapy for head and neck cancer HNSCC: indications and modalities Prof. dr. Sandra Nuyts Radiotherapy-Oncology
Radio(chemo)therapy for head and neck cancer HNSCC: indications and modalities Prof. dr. Sandra Nuyts Radiotherapy-Oncology March 2018 > Half million new cases HNC/year in world 50-60% cured not cured
More informationExpanding Role of the Medical Oncologist in the Management of Head and Neck Cancer Nicholas Choong and Everett Vokes DOI: /CA.2007.
Expanding Role of the Medical Oncologist in the Management of Head and Neck Cancer Nicholas Choong and Everett Vokes CA Cancer J Clin 2008;58;32-53; originally published online Dec 20, 2007; DOI: 10.3322/CA.2007.0004
More informationAdjuvant chemo- and radiotherapy for poor prognosis head and neck squamous cell carcinomas
Critical Reviews in Oncology/Hematology 56 (2005) 353 364 Adjuvant chemo- and radiotherapy for poor prognosis head and neck squamous cell carcinomas Jacques Bernier a,, David G. Pfister b, Jay S. Cooper
More informationSequencing Chemo with Radiation therapy Locally Advanced Head and Neck Cancer. Dr P Vijay Anand Reddy Director Apollo Cancer Hospital
Sequencing Chemo with Radiation therapy Locally Advanced Head and Neck Cancer Dr P Vijay Anand Reddy Director Apollo Cancer Hospital H&N Ca - Disease Burden 15-20% of all cancers in India, 8% worldwide
More informationThe role of chemoradiotherapy in GE junction and gastric cancer. Karin Haustermans
The role of chemoradiotherapy in GE junction and gastric cancer Karin Haustermans Overview Postoperative chemoradiotherapy Preoperative chemoradiotherapy Palliative radiation Technical aspects Overview
More informationEvaluation of Whole-Field and Split-Field Intensity Modulation Radiation Therapy (IMRT) Techniques in Head and Neck Cancer
1 Charles Poole April Case Study April 30, 2012 Evaluation of Whole-Field and Split-Field Intensity Modulation Radiation Therapy (IMRT) Techniques in Head and Neck Cancer Abstract: Introduction: This study
More informationSALIVARY GLAND TUMORS TREATED WITH ADJUVANT INTENSITY-MODULATED RADIOTHERAPY WITH OR WITHOUT CONCURRENT CHEMOTHERAPY
doi:10.1016/j.ijrobp.2010.09.042 Int. J. Radiation Oncology Biol. Phys., Vol. 82, No. 1, pp. 308 314, 2012 Copyright Ó 2012 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/$ - see front
More informationThe Role of Docetaxel in the Treatment of Head and Neck Cancer
GBMC Head and Neck Conference The Role of Docetaxel in the Treatment of Head and Neck Cancer Simon Best December 7, 2007 Needs assessment: Providers who participate in the care of head and neck cancer
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More information